The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Table 2

Comparison of PASI, VAS, and DLQI scores in placebo and treatment groups at the baseline, weeks 4, 8, and 12.

Variables	Treatment	SEM	Placebo	SEM	value
PASI baseline	7.22	0.61	6.47	0.42	0.31
VAS baseline	57.64	4.64	50.29	5.31	0.30
DLQ baseline	11.88	0.90	9.81	1.09	0.15
PASI week 4	6.7	.60	6.44	0.41	0.72
VAS week 4	50.44	4.51	49.51	5.18	0.89
DLQI week 4	10.76	0.83	9.70	1.01	0.42
PASI week 8	5.67	0.49	6.33	0.39	0.29
VAS week 8	41.80	4.43	48.51	4.94	0.32
DLQI week 8	8.96	0.73	9.40	0.86	0.69
PASI week 12	4.08	0.28	6.19	0.39	<0.001
VAS week 12	32.24	4.29	48.11	4.88	0.019
DLQI week 12	6.56	0.63	8.92	0.71	0.017